Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | TNKS | O95271 | 6/20 | 0.57 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.55 |
| ▸ | SPR | P35270 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148644 | 0.97 | KDM4E (0.66) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL129916 | 0.82 | TNKS (0.52) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL129507 | 0.82 | FGFR1 (0.49) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL171064 | 0.80 | FGFR1 (0.47) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL10150421 | 0.80 | FGFR1 (0.47) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL1034183 | 0.79 | HPGD (0.62) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL13851577 | 0.78 | HPGD (0.57) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL13851590 | 0.77 | TNKS2 (0.45) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL1035972 | 0.77 | HPGD (0.71) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL1036534 | 0.77 | HPGD (0.71) | KDM4EALDH1A1HPGDTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | KCNQ1, KCNN2, KCNH3 | KDM4E 2477/4885ALDH1A1 3086/4885HPGD 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.